The mechanisms of compromised mitochondrial function under various pathological conditions, including hypoxia, remain largely unknown. Recent studies have shown that microRNA-210 (miR-210) is induced by hypoxia under the regulation of hypoxia-inducible factor-1a and has an important role in cell survival under hypoxic microenvironment. Hence, we hypothesized that miR-210 has a role in regulating mitochondrial metabolism and investigated miR-210 effects on mitochondrial function in cancer cell lines under normal and hypoxic conditions. Our results demonstrate that miR-210 decreases mitochondrial function and upregulates the glycolysis, thus make cancer cells more sensitive to glycolysis inhibitor. miR-210 can also activate the generation of reactive oxygen species (ROS). ISCU (iron-sulfur cluster scaffold homolog) and COX10 (cytochrome c oxidase assembly protein), two important factors of the mitochondria electron transport chain and the tricarboxylic acid cycle have been identified as potential targets of miR-210. The unique means by which miR-210 regulates mitochondrial function reveals an miRNAmediated link between microenvironmental stress, oxidative phosphorylation, ROS and iron homeostasis.
Introduction
Hypoxia is known to have an important role in various physiological processes and pathological conditions, including cancer, Parkinson's disease, myocardial ischemia/ reperfusion and stroke. A hypoxic microenvironment can cause mitochondrial dysfunction and activate various signaling pathways through hypoxia-inducible factor-1a (HIF-1a). The activation of HIF-1a can trigger various biological events, including activation of the glycolytic pathway, increased blood vessel formation and downregulation of mitochondrial activity through pyruvate dehydrogenase kinase-1 (Papandreou et al., 2006; Bristow and Hill, 2008) .
MicroRNAs (miRNAs) are small noncoding RNAs that silence the expression of target genes through either mRNA degradation or suppression of transcription procedure. miRNAs have roles in almost all aspects of cell biology, and their deregulation has been reported in various diseases, especially cancer (Lee and Dutta, 2009 ). Recently, a specific group of hypoxia-regulated miRNAs that are under the regulation of HIF-1a was identified. miR-210 is one of the most hypoxia-sensitive miRNAs, and its overexpression protected breast cancer cells from hypoxia-induced apoptosis (Kulshreshtha et al., 2007) . miR-210 has also been shown to have a role in cell cycle regulation (Giannakakis et al., 2008) and DNA damage and repair (Crosby et al., 2009) . However, whether miR-210 has role in compromised mitochondrial function under hypoxic conditions remain unknown. We thus hypothesized that miR-210 regulates mitochondrial function by targeting key electron transport/tricarboxylic acid cycle genes and investigated its effects on mitochondrial function in cancer cells.
Results and Discussion

Hypoxia and chemical mimetic regulate miR-210
We first confirmed that miR-210 expression is upregulated by hypoxia in different cancer cell lines using quantitative real-time PCR analysis. Cell lines tested included the colon cancer cell lines HCT116, HCT116 p53À/À (HCTÀ/À), HT29 and RKO; breast cancer cell line MCF-7; esophageal adenocarcinoma cell line BE3. The HCTÀ/À cells were derived from HTC116 cells with wild-type p53 through somatic disruption of p53 (Bunz et al., 1998) . In agreement with previous publications (Kulshreshtha et al., 2007) , substantial induction of miR-210 expression was observed in every cell line tested ( Figure 1a) . The iron chelator deferoxamine mesylate (DFO), widely used as a hypoxia mimetic that induces accumulation of HIF-1a, also induced miR-210 expression in the same set of cell lines (Figure 1b) . miR-210 downregulates mitochondrial respiration and mediates metabolic switch to glycolysis To test whether miR-210 is able to regulate mitochondrial respiratory activity, HCT116 cells were transfected with miRNA mimic of miR-210 and oxygen consumption activity was measured. Exposure to miR-210 mimic for 48 h resulted in an approximately 24% reduction in the oxygen consumption rate (Figure 2a) . Similar result was observed in HCTÀ/À cells (data not shown).
Lactate acid, the end product of the glycolysis pathway, increases under circumstances of cellular hypoxia or mitochondrial dysfunction because cells have to upregulate glycolysis activity to meet their demand for ATP and metabolic intermediates. If miR-210 does inhibit mitochondrial respiratory activity, one would expect to observe elevated lactate levels. Hence, we measured lactate levels in culture medium after the treatment of HCT116 cells with miR-210 mimic. As illustrated in Figure 2b , treatment with miR-210 mimic resulted in increased lactate levels compared with the mimic-negative control.
Cytotoxicity assay indicated that this metabolic switch was accompanied by an elevated sensitivity to 3-brommo-2-oxopropionate-1-propyl ester (3-BrOP), which is a potent inhibitor of the glycolysis pathway targeting the hexokinase enzyme (Figure 2c ). 3-BrOP is known to preferentially kill cancer cells with elevated glycolytic activity (Chen et al., 2007) . These data suggested that miR-210 can trigger the metabolic switch from aerobic respiration to glycolysis. This metabolic switch was unlikely due to the initiation of cell death, as these cells did not undergo apoptosis, although cell proliferation did appear to slow down, as described below (Figure 3 ). Effects of miR-210 on cell proliferation, membrane potential and ROS miR-210 mimic started having a moderate inhibitory effect on the proliferation rate of HCT116 cells 48 h post-transfection ( Figure 3a ). This observation is supported by a recent publication showing that miR-210 has a role in cell cycle regulation (Giannakakis et al., 2008) . Meanwhile, miR-210 had no noticeable effect on mitochondrial membrane potential in HCT116 or HCTÀ/À cells within 48 h after transfection ( Figure 3b ). Mitochondrial membrane potential is an important parameter of mitochondrial function and has been widely used as an indicator of cell health. Our data indicate that although cell proliferation moderately slowed down, there was no apparent cell death caused by increased miR-210 levels.
Elevated oxidative stress has been observed in many cancer cell types, which correlates with the aggressiveness of tumors and poor prognosis. Reactive oxygen species (ROS) can activate various survival pathways, promote genetic instability and render cells resistant to drug treatment (Trachootham et al., 2009) . The production of ROS can be triggered by hypoxia and mitochondria initiated ROS can stabilize HIF-1a by partially inhibiting prolyl hydroxylase activity (Guzy et al., 2005) . We, therefore, questioned whether miR-210 also contributes to the induction of ROS under hypoxic conditions. As illustrated in Figures 3c and d, treatment with miR-210 mimic activated the generation of hydrogen peroxide (H 2 O 2 ) and superoxide within 24 or 48 h after transfection. The amount of H 2 O 2 induced was more significant than that of superoxide, and similar observations were made in HCT116 and HCTÀ/À cells. One possible explanation is that accumulated superoxide is readily converted into H 2 O 2 by enzymes called superoxide dismutases. These results indicate that miR-210 negatively regulates mitochondrial respiration activity and activates ROS generation, which may contribute to cell survival under hypoxic microenvironment.
ISCU and COX10 are target genes of miR-210 related to mitochondrial metabolism
We first attempted to identify miR-210's target genes associated with mitochondrial metabolism by in silico prediction algorithms using Sanger miRBase (http:// www.microrna.sanger.ac.uk/) and TargetScan (http:// www.targetscan.org/). We identified several promising putative miR-210 target genes related to OXYPHOS (oxidative phosphorylation), including ISCU (ironsulfur cluster scaffold homolog), COX10 (cytochrome c oxidase assembly protein), CS (citrate synthase), NDUFA4 (NADH dehydrogenase (ubiquinone) 1a subcomplex), SDHALP2 (succinate dehydrogenase complex, subunit A, flavoprotein pseudogene 2) and NOX4 (NADPH oxidase 4). We observed that the mRNA levels of two of these targets, ISCU and COX10, were consistently downregulated in HCT116, HCTÀ/À, HT29 and RKO cells under hypoxia or DFO treatment, which lead to robust induction of miR-210. This Figure S1) . To test if ISCU and COX10 are targets of miR-210, we first evaluated their mRNA levels in HCT116 cells after transfection with miR-210 mimic under normoxic condition. mRNA levels of ISCU and COX10 under normoxic culture conditions were significantly decreased after transfection with miR-210 mimic compared with the miRNA mimic-negative control (Figure 4a ). We then determined if treatment with miR-210 hairpin inhibitor under hypoxic conditions could abrogate the reduction of ISCU or COX10 mRNA level caused by hypoxia. As shown in Figure 4a , the reduction of mRNA level under hypoxic conditions was abrogated by transfection with the miR-210 hairpin inhibitor compared with the miRNA inhibitor negative control, which indicate that miR-210 is the major cause of downregulation of ISCU and COX10 genes under hypoxic condition. A similar trend was observed in three additional cancer cell lines tested (Supplementary Figure S2) .
We next used the luciferase reporter gene assay to confirm that miR-210 directly targets mRNA of ISCU and COX10 by cloning the 3 0 -UTR regions of ISCU and COX10 mRNA separately into the luciferase reporter plasmid pGLS3 control vector. Co-transfection of HCT116 cells with pGLS3 vector and miR-210 mimic resulted in 40 and 70% reduction of luciferase activity of ISCU and COX10, respectively. miR-210 mimic had no effect on the pGLS3 vector containing the reverse sequences of the ISCU and COX10 3 0 -UTR regions (Figure 4b ). Downregulation of ISCU and COX10 by miR-210 was further confirmed at the protein level by western blot analysis (Figure 4c) .
To confirm the specificity of miR-210's regulation of ISCU and COX10, we tested the effect of altering miR-210 levels on additional genes encoding subunits of the electron transport chain under similar experimental conditions as described in Figure 4a (Supplementary Figure S3) . Genes we tested are NDUFA4 (complex I subunit), SDHALP2 (complex II subunit) and COX15 (complex IV subunit). Among them, NDUFA4 has been picked up by in silico prediction algorithms as potential target of miR-210. The results confirm that miR-210 mimic or inhibitor treatment does not significantly alter mRNA level of these three additional genes we tested.
To determine that repression of ISCU and COX10 contributes to miR-210-mediated effects on mitochondria function, we performed knockdown experiments using small interfering RNA targeting ISCU and COX10. As shown in Supplementary Figure S4 A miR-210 regulates mitochondria and targets ISCU COX10 Z Chen et al cytochrome P450 enzymes, the upregulation of ROS production caused by miR-210 is likely due to yet unidentified targets of miR-210, which appear to be many according to in silico prediction algorithms.
We further tested whether overexpression of the coding region of ISCU (without 3 0 -UTR region, thus, missing miR-210 target sequence) can reverse the effects of miR-210 on mitochondrial respiration. Constructs of the coding regions of ISCU1/2 were generated using pcDNA3.1 vector, and stable HCT116 cell lines expressing those vectors were established. MiR-210 mimic treatment caused significantly less repression at the protein levels of ISCU1/2 in stable HCT116 cells expressing ISCU1/2. Furthermore, the downregulation of mitochondrial respiration activity caused by miR-210 mimic was partially reversed in the presence of constitutively expressed ISCU1/2 (Supplementary Figure S4 C and D) . Unfortunately, we were unable to establish a stable cell line overexpressing COX10 due to technical issues for validating causative role of COX10.
ISCU is essential for the assembly of Fe-S clusters, which are major components in the mitochondrial electron transport chain/tricarboxylic acid cycle and define the electron transport pathways in redox enzymes (Johnson et al., 2005) . Loss of function of ISCU can cause decline of mitochondrial function and disrupt iron homeostasis (Tong and Rouault, 2006) . COX10 encodes a protoheme: heme O farnesyl transferase that participates in the biosynthesis of heme-a, which is an essential component of COX (cytochrome c oxidase, complex IV). The loss of function of COX10 can cause suppression of mitochondrial function at the level of both complex I and IV (Diaz et al., 2006) .
The possibility that ISCU and COX10 are under direct regulation of miR-210 indicates that miR-210 may have a role in the regulation of the mitochondria electron transport chain and tricarboxylic acid cycle. It is interesting to note that DFO treatment increased miR-210 expression and decreased the mRNA levels of ISCU and COX10. Given the fact that DFO and other hypoxia mimetics (2, 2 0 -dipyridyl and C O Cl 2 ) are all iron chelators, there might be an intrinsic correlation between hypoxia and cellular iron homeostasis, and miR-210 may have an important role in iron metabolism.
In conclusion, our data demonstrate that miR-210, which is a highly upregulated miRNA induced by hypoxia, can negatively regulate mitochondrial respiration activity and increase ROS generation. ISCU and COX10 genes, which are key factors of the mitochondrial electron transport chain and the tricarboxylic acid cycle, have been identified as potential targets of miR-210. Our results confirm causative role of ISCU1/2 in miR-210 modulated mitochondrial respiration; further experimentation is required to validate similar role for COX10. As loss of function of both ISCU and COX10 seems to have no effect on ROS generation, the mechanism of miR-210's effect on cellular ROS needs to be further investigated. Given that hypoxia/HIF-1a pathway is capable of triggering the metabolic switch from respiration to the glycolytic pathway (the Warburg effect) and promoting tumor cell survival under hypoxic conditions (Papandreou et al., 2006; Hsu and Sabatini, 2008) , our study indicates that miR-210 has an important role in cancer cells' adaptation to hypoxic microenvironment. This is supported by observations that expression of miR-210 is elevated in pancreatic cancer (Greither et al., 2010) , diffuse large B-cell lymphoma (Lawrie et al., 2008) and breast cancer (Camps et al., 2008) .
The discovery that hypoxia-regulated miRNA decreases mitochondrial respiration activity and activates ROS generation provides a better understanding of cancer cell metabolism and may serve as a biochemical basis for developing new chemotherapy strategies. Future studies are warranted to see if miR-210 has a role in other hypoxia-and mitochondrial dysfunctionrelated diseases such as Parkinson's disease, myocardial ischemia and stroke.
Materials and methods
Reagents DFO was purchased from Sigma-Aldrich (St Louis, MO, USA). TRIzol reagent was from Invitrogen (Carlsbad, CA, USA). 3-BrOP (cell-permeable ester of 3-bromopyruvate) and human colon cancer cell lines HCT116 and HCT116 p53À/À (HCTÀ/À) were gifts from Dr Peng Huang. miRNA miRIDIAN mimic, hairpin inhibitor and relative negative controls, ON-TARGETplus SMARTpool small interfering RNA for ISCU and COX10, DharmaFECT 1 and DharmaFECT Duo Transfection reagent were from Dharmacon (Chicago, IL, USA). Lipofectamine 2000 was from Invitrogen (Carlsbad, CA, USA). TaqMan miRNA assays for hsa-miR-210, hsamiR-16, and RNU48 and TaqMan gene expression assays for ISCU and COX10 were from Applied Biosystems (Foster City, CA, USA). pGL3 luciferase reporter control vector and the Dual Luciferase Reporter Assay System kit were from Promega (Madison, WI, USA). ISCU and COX10 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell culture and treatment
Colon cancer cells (HCT116, HCTÀ/À, HT29 and RKO) were cultured in McCoy's 5A medium supplemented with 10% fetal bovine serum. MCF-7 and BE3 cells were maintained in Dulbecco's modified Eagle's medium F12 medium supplemented with 10% fetal bovine serum. The hypoxic culture condition (2% O 2 ) was reached by culturing cells in a modular incubator chamber (Billups-Rothenberg, Del Mar, CA, USA) flushed with 2% O 2 , 5% CO 2 and 95% N 2 . The working concentration of DFO was 50 mM.
Mitochondrial membrane potential and cellular ROS To measure mitochondrial membrane potential, the fluorescent dye rhodamine 123 (1 mM) was applied. To measure cellular superoxide or H 2 O 2 levels, 100 ng/ml dihydroethidium or 3 mM DCF-DA (CM-H 2 DCFDA) were applied. Samples were analyzed by flow cytometry (Pelicano et al., 2003) .
Oxygen consumption and lactate generation After trypsinization, 3 million HCT116 cells were sealed in the respiration chamber containing a Clark-type oxygen electrode disc (Oxytherm; Hansatech Instrument, Cambridge, UK). The miR-210 regulates mitochondria and targets ISCU COX10 Z Chen et al oxygen consumption rate was calculated and plotted as described previously (Pelicano et al., 2003) . The cellular lactate production was analyzed using an Accutrend lactate analyzer (Roche, Mannheim, Germany) according to the manufacturer's instructions and normalized by cell amount.
Western blot analysis
Western blot analysis of miR-210 mimic-treated cells was performed as described previously (Pelicano et al., 2003) .
Quantitative real-time PCR analysis for mRNA and miRNA Total RNA was isolated using TRIzol reagent, following the manufacturer's protocol (Invitrogen). For mRNA expression profile of ISCU and COX10, real-time PCR analysis was performed using TaqMan gene expression assays as described previously (Luthra et al., 2008) . GUSB (glucuronidase b) was used as the normalization control. miR-210 levels were determined by TaqMan MicroRNA assay using stem-loop real-time quantitative PCR analysis (Applied Biosystems). miR-16 or RNU48 were applied as normalization controls. As the levels of miRNAs, including miR-16 and RNU48, fluctuated significantly after hypoxia treatment, the miR-210 expression levels after hypoxia were normalized to the normoxic samples.
Luciferase reporter assay
The 3 0 -UTR regions of ISCU and COX10 containing the predicted binding sites of miR-210 were amplified separately from normal female genomic DNA by PCR using the following specific primers: ISCU forward primer, 5 0 -tagtctag agccctccctcggcgaag-3 0 ; reverse primer, 5 0 -gcgtctagaactagagaac accatcatc-3 0 . COX10 forward primer, 5 0 -tagtctagagagcactggga cgcccac-3 0 ; reverse primer, 5 0 -tcgtctagaaggccctggctcagtcac-3 0 . The oligonucleotide duplexes were cloned into the PGL3 control vector at the XbaI site in the correct and reverse (negative control) directions. Co-transfection and measurement of luciferase activity were performed as described previously (Luthra et al., 2008) .
Cytotoxicity and proliferation assay
After transfection with miR-210 mimic for 24 h, HCT116 cells were trypsinized and re-plated into 96-well plates. After 24 h, different concentrations of 3-BrOP were added and incubated for an additional 72 h. The cytotoxicity of 3-BrOP was analyzed as described previously (Xu et al., 2005) . Cell proliferation assay was performed using MTT assay (Luthra et al., 2008) .
Small interfering RNA and miRNA mimic/inhibitor transfection The transfection of small interfering RNA of ISCU and COX10, miRNA mimic of miR-210, miR-210 hairpin inhibitor were performed following the manufacturer's protocol (Dharmacon). The working concentration of RNA was 100 nM.
Establishment of stable cell lines expressing coding regions of ISCU1/2 and COX10 The coding regions (without 3 0 -UTR) of ISCU1, ISCU2 and COX10 were amplified separately from normal female genomic cDNA by PCR using the following specific primers: ISCU1 forward primer, 5 0 -cttaagcttatggttctcattgacatg-3 0 ; reverse primer, 5 0 -cggaattctcatttcttctctgcctc-3 0 . ISCU2 forward primer, 5 0 -cttaagcttatggcggcggctgggg-3 0 ; reverse primer, 5 0 -cggaattctcatttcttctctgcctctcc-3 0 . COX10 forward primer, 5 0 -accaagcttatggccgcatctccgcacac-3 0 ; reverse primer, 5 0 -cggaattct cagctgggagggggcc-3 0 . Constructs were generated using pcDNA3.1( þ ) vector, and stable HCT116 cell lines expressing ISCU1/2 and COX10 were established using Lipofectamine 2000, following the manufacturer's protocol (Invitrogen).
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